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doi:10.1016/j.jtcvs.2008.02.016Objective: Patients with advanced esophageal squamous cell carcinoma receive neo-
adjuvant chemotherapy or chemoradiotherapy to improve survival, but benefits are
observed only in those with histologic response. Positron emission tomography
with fludeoxyglucose F 18 (INN fludeoxyglucose [18F]) detects accumulation of
glucose analog in viable cancer cells. This study investigated the usefulness of posi-
tron emission tomography with fludeoxyglucose F 18 in assessment of response of
advanced esophageal squamous cell carcinoma to neoadjuvant treatment to establish
new criteria to predict postoperative long-term survival.
Methods: Fifty patients with locally advanced esophageal squamous cell carcinoma
who received neoadjuvant therapy (chemotherapy 35, chemoradiotherapy 15) under-
went positron emission tomography with fludeoxyglucose F 18 before surgical resec-
tion in evaluation of posttreatment maximum standardized uptake value, residual
tumor size (maximum square area of longitudinal axis), histologic response, and post-
operative survival.
Results:After treatment, uptake was not noted in 21 patients (posttreatment maximum
standardized uptake value ,2.5, negative) but was detected in 29 ($2.5, positive).
Residual tumor size ranged from 0 to 54.0 mm2 for negative results and 55.0 to
676.0 mm2 for positive, clearly distinguishing histologic major response from nonre-
sponse. The negative group demonstrated significantly higher 5-year cause-specific
survival (67.7%) and lower hematogenous recurrence (4.8%) than the 36.5% and
37.0% values in the positive group, (P, .0042 and P5 .0083, respectively). Univar-
iate Cox regression analyses identified posttreatment maximum standardized uptake
value (cutoff 2.5) as the only preoperative prognostic factor (P 5 .0071).
Conclusion: Posttreatment positron emission tomography with fludeoxyglucose F 18
reliably predicted histologic response and postoperative survival in advanced esoph-
ageal squamous cell carcinoma. This tool could potentially be used to tailor optimal
treatment according to individual responses.
N
eoadjuvant chemotherapy and chemoradiotherapy have been used to
improve the survival of patients with locally advanced esophageal carci-
noma. No survival benefits have been observed, however, in patients without
histologic response.1-6 It is important to distinguish those with histologic response and
to tailor subsequent treatment. Treatment response has been evaluated clinically by
detection of relative morphologic changes in tumor size with computed tomography,
barium study, and endoscopic ultrasonography. All these diagnostic modalities areThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 1 205
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FDG 5 fludeoxyglucose F 18
PET 5 positron emission tomography
SCC 5 squamous cell carcinoma
SUVmax 5 maximum standardized uptake value
inadequate for use in clinical decision making, however,
because local fibrosis and cicatricial stenosis often hinder
accurate assessment, diluting any correlation with histologic
response.7-10
Positron emission tomography (PET) with fludeoxyglu-
cose F 18 (FDG, INN fludeoxyglucose [18F]) is a metabolic
imaging modality that allows detection and visualization of
accumulated glucose analogs in viable malignant tumor cells.
FDG uptake reflects the volume and activity of viable cancer
cells, even after neoadjuvant treatment. Thus the difference in
uptake before and after treatment should reflect clinical
response, and the posttreatment FDG uptake should indicate
residual tumor volume and viability (histologic response).
Several preliminary studies have suggested the usefulness
of FDG-PET for evaluation of the response to chemotherapy
or chemoradiotherapy in esophageal carcinoma.11-24 Most of
these have been preliminary reports of small-scale studies,
however, so the usefulness of FDG-PET in response evalua-
tion has not yet been established. Furthermore, the studies
have examined mainly patients with adenocarcinoma, not
with squamous cell carcinoma (SCC), which is the most com-
mon cell type in Japan. To our knowledge, there has been no
large-scale report of patients with esophageal SCC.
The purpose of this study was to investigate whether
FDG-PET could predict histologic response and postopera-
tive survival in large number of patients with esophageal
SCC and to establish a new, distinct standard for FDG-PET
assessment. We prospectively evaluated pretreatment and
posttreatment FDG-PET scans and compared the findings
with residual tumor volume, histologic response, postopera-
tive survival, and failure pattern.
Materials and Methods
Study Design and Patients
This study was a single-arm, prospective, single-institution clinical
trial. Patients with histologically confirmed T3 SCC tumors without
hematogenousmetastasis were eligible for enrollment. OfM1 lymph
nodes, supraclavicular and celiac artery lymph nodes that existed in
the region of three-field lymphadenectomy were included. To com-
pare FDG uptake of PET and histologic response, we excluded
patients with unresectable T4 tumors. Other exclusion criteria
were diabetes mellitus, history of previous treatment of the same dis-
ease, presence of another active malignant disease, and severe func-
tional visceral or mental disorder. Of 356 patients with esophageal
SCC who were treated at Osaka University Hospital between March
2000 and August 2004, a total of 50 patients who fulfilled these cri-206 The Journal of Thoracic and Cardiovascular Surgery c Julyteria were enrolled in this study (Table E1). Patients underwent con-
ventional staging with barium esophagography, gastroesophageal
endoscopy, and computed tomography, followed by FDG-PET.
These patients then received either neoadjuvant chemotherapy or
chemoradiotherapy, followed by repeated conventional staging
and FDG-PET approximately 2 or 4 weeks after completion of
chemotherapy or chemoradiotherapy, respectively. Finally, patients
underwent surgical resection within 2 weeks after the second FDG-
PET. Initial and repeated conventional staging, second FDG-PET,
and neoadjuvant treatment were completed in all cases. The pretreat-
ment FDG-PET could not be performed in 7 cases, however, because
of inconvenient examination schedules. Informed consent was ob-
tained from all patients, and the study was approved by the High-De-
gree Advanced Medical Committee of Osaka University Hospital.
Neoadjuvant Treatment
Patients confirmed to have no FDG uptake in any lymph node on
PET underwent chemoradiotherapy, whereas those with FDG accu-
mulation in any lymph node received chemotherapy for systemic
and local control. The regimen of chemoradiotherapy consisted of
concurrent external beam radiotherapy (4 weeks, 5 d/wk, 40 Gy to-
tal), bolus infusion of cisplatin at a dose of 7 mg/m2, and continuous
infusion of fluorouracil at 350 mg/m2 (4 weeks, 5 d/wk). The radi-
ation field included all regional lymph node areas. The chemother-
apy consisted of two cycles of combination protocol of bolus
infusion of cisplatin at 70 mg/m2 and doxorubicin at 30 mg/m2 on
day 1 and continuous infusion of fluorouracil at 1000 mg/d on
days 1 to 7. The courses were repeated twice every 28 days.
FDG-PET Imaging
Whole-body FDG-PET imaging was performed as reported previ-
ously.25-27 Briefly, each patient fasted for at least 4 hours before
intravenous administration of approximately 370 MBq FDG. Serum
glucose levels were determined just before FDG injection. All pa-
tients were normoglycemic (blood glucose ,150 mg/dL). Simulta-
neous emission and transmission PET scans were acquired 1 hour
after FDG injection (transmission source 68Ge-68Ga line source).
Then imaging was performed with a dedicated PET scanner
(HEADTOME/SET 2400W; Shimadzu Co, Kyoto, Japan).
For semiquantitative analysis, regions of interest were selected
semiautomatically at the most intense area of FDG accumulation
in the primary tumor on the PET image, and the maximum standard-
ized uptake value (SUVmax) was calculated according to the follow-
ing formula: PET count at most intense point 3 calibration factor
(MBq/kg)/injection dose (MBq)/body weight (kg). Primary tumors
with SUVmax at least 2.5 were considered to have a positive result,
because FDG uptake at SUVmax less than 2.5 is invisible. When
there was no visible FDG uptake, the fusion images combined
with PET images and computed tomographic images were com-
posed with our previously described method, regions of interest
were drawn exactly on the area corresponding to the primary tumor,
and the SUVmax was calculated.
26
Surgical Treatment
The surgical procedure consisted of transthoracic subtotal esophagec-
tomy and reconstruction of the gastric tube in tumors of the thoracic
esophagus. Three-field lymphadenectomywas performed for patients
with upper-third thoracic tumors or lymph node metastases along the
recurrent laryngeal nerves,28 and two-field lymphadenectomy was2008
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underwent partial esophageal resection and bilateral neck lymphade-
nectomy, followed by reconstruction with a free jejunal graft.
Histopathologic Evaluation
Resected primary tumors were embedded in paraffin after fixation
with formaldehyde, and serial sections of each block were cut and
stained with hematoxylin and eosin. Conventional histologic
examination was performed in all cases. Histopathologic response
was classified in accordance with the guidelines of the Japanese
Society for Esophageal Diseases29 as follows: grade 3 was complete
disappearance of cancer cells, grade 2 was more than two-thirds
disappearance, grade 1 was less than one-third disappearance, and
grade 0 was no disappearance. Histologically good response was
defined as grade 2 or 3 response; this definition was based on our
previous results of patients with clinical T4 esophageal SCC who
underwent surgery after chemoradiotherapy with 3-year survivals
of 85.7% for grade 3, 45.8% for grade 2, and 0% for grade 1.2
Tumor size was expressed as the square area of the longitudinal
maximum dimension of the tumor. A photograph of the maximal
section was stored in the computer as an image file, and tumor
size was measured with appropriate software (NIH Image 1.62 for
the Mac. Download at http://rsb.info.nih.gov/nih-image).
Statistical Analysis
The relationship between FDG uptake (SUVmax) and tumor size was
determined with the Pearson correlation coefficient. Comparisons of
histologic responses according to posttreatment FDG-PET results
were analyzed with theMann—WhitneyU test. Independent predic-
tive factors for survival were determined with Cox regression
analysis. Univariate analyses and comparisons of the two groups
with regard to patterns of failure were performed with the c2 test.
Survival was calculated from the initial date of treatment to the oc-
currence of the event or date of the most recent follow-up visit.
Cause-specific and disease-free survivals were calculated by the Ka-
plan–Meier method. The significances of prognostic variables for
outcome were calculated by log-rank test.
Results
Patient Characteristics
Fifty patients were included in this study (Table E1). The
median age was 62.2 years (range 44–77 years). Cervical
esophageal tumors were observed in 11 patients, with the
remaining tumors located in the thoracic esophagus (upper
in 5 patients, middle in 17, and lower in 17). The initial clin-
ical stage was III or more, with T3 tumors in all 50 patients
(III in 24 patients, IVA in 11, and IVB in 15). On the basis
of the pretreatment diagnosis of lymph node metastases,
15 patients received chemoradiotherapy; the remaining 35
patients underwent chemotherapy followed by surgery. R0
resection was performed in 48 cases, with only 2 patients un-
dergoing R2 resection because of invasion of the right pul-
monary vein in 1 case and the left main bronchus in the
other. There were no postoperative deaths.
FDG Uptake and Tumor Size
We first examined the correlation between posttreatment
SUVmax of the primary tumor measured by FDG-PET andThe Journal of Thorthe square area of the longitudinal maximum dimension of
the resected tumor (tumor size). The posttreatment SUVmax,
as shown in Figure 1, correlated significantly with the residual
tumor size (r5 0.898, P, .0001), with a regression equation
of y 5 0.025 3 x 1 1.634. This result suggests that residual
tumor size could be predicted by posttreatment SUVmax.
Histologic Response and Residual Tumor Size
Histologic response grades were as follows: 8 patients with
grade 0, 22 with grade 1, 14 with grade 2, and 6 with grade
3 (Figure E1). As mentioned in the Methods section, a histo-
logic response of at least grade 2 was necessary for long sur-
vival, as described in our previous report.2 Figure E1 shows
the distribution of residual tumor size according to the histo-
logic response. The tumor size ranged from 55 to 672 mm2
for grade 0, 1.3 to 676 mm2 for grade 1, 0.9 to 102 mm2
for grade 2, and was defined as 0 mm2 for grade 3 (no tumor),
demonstrating a distinct difference between grade 1 or lower
nonresponse and grade 2 or better response. When the cutoff
value was set at 33 mm2, as shown in Figure E1, the sensitiv-
ity and specificity for accuracy of histologic response were
the highest, 94.7% and 93.5%, respectively, suggesting that
posttreatment residual tumor size less than 33 mm2 might
indicate grade 2 or better histologic response.
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Figure 1. Correlation between tumor size (maximum cross-sec-
tional area of resected tumor) and posttreatment maximum stan-
dardized uptake value (SUVmax) in primary tumor. Posttreatment
maximum standardized uptake value and tumor size ranged from
1.03 to 25.62 and from 0 mm2 to 676.0 mm2, respectively n 5 50,
y 5 0.025 3 x 1 1.634, r 5 0.898, R2 5 0.806, P < .0001).acic and Cardiovascular Surgery c Volume 136, Number 1 207
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To determine the standard value of FDG-PET to predict his-
tologic response, we calculated posttreatment SUVmax corre-
sponding to residual tumor of 33 mm2 according to the
formula of the expression of regression obtained in Figure 1.
The result was 2.459, but FDG accumulation with SUVmax
less than 2.5 cannot be detected by PET. We therefore classi-
fied patients with posttreatment SUVmax less than 2.5 as hav-
ing a response. This response evaluation could be assessed by
visual inspection, and posttreatment SUVmax values less than
2.5 and greater than or equal to 2.5 were designated as nega-
tive (Figure E2) and positive PET results, respectively.
Posttreatment PET Diagnosis and Histologic
Response
All 50 patients were assessed again with this new standard of
treatment response evaluation. They were classified as 21
with negative PET (response, chemotherapy 13, chemoradio-
TABLE 1. Relationship between posttreatment positron
emission tomographic diagnosis and histologic response
Posttreatment PET diagnosis
Positive Negative
No. of patients 29 21
Residual tumor size (mm2)
Mean 238.8 12.8
Range 55–676 0–54
Histologic response (No.)
Grade 0 8 0
Grade 1 19 3
Grade 2 2 11
Grade 3 0 7
Grade 2–3* 2 (6.9%) 18 (85.7%)
PET, Positron emission tomographic. *P , .0001.208 The Journal of Thoracic and Cardiovascular Surgery c Jultherapy 8) and 29 with positive PET (nonresponse, chemo-
therapy 22, chemoradiotherapy 7). The residual tumor size
ranged from 0 to 54 mm2 (average 12.8 mm2) in the negative
PET group and 55 to 676.0 mm2 (average 238.8 mm2) in the
positive PET group (Table 1). Negative PET results indicated
that residual tumor was less than 55 mm2. With regard to the
grade of histologic response, 18 (85.7%) patients of the
negative PET group showed grade 2 or better histologic re-
sponse, whereas only 2 in the positive PET group showed
such high histologic response (6.9%, P , .0001; Table 1).
Consequently, the sensitivity, specificity, and accuracy of
posttreatment PET diagnosis for prediction of grade 2 or
better histologic major response were 85.7%, 93.1%, and
90.0%, respectively.
Posttreatment PET Diagnosis and Survival After
Surgery
We evaluated the ability of posttreatment SUVmax to predict
postoperative long-term survival. The median follow-up was
26.5 months (range 5.4–84.2 months). During this period, 4
patients died of other diseases without recurrence: 3 in the neg-
ative PET group of aneurysm, pneumonia, and hepatocellular
carcinoma and 1 in the positive PET group of pneumonia.
Tumor recurrence was identified in 25 patients, 7 in the nega-
tive PET group and 18 in the positive PET group. All
patients, with recurrence, were dead at the end of the follow-
up period, except for 1 in the negative PET group. Especially
of note, 7 patients, with recurrence, in the positive PET group
died within 1 year after initiation of neoadjuvant therapy.
The cause-specific median survival was longer than 84.2
months in the negative PET group and was 18.2 months in
the positive PET group. The 1-, 3- and 5-year cause-specific
survivals were 95.0%, 73.9%, and 67.7%, respectively, in the
negative PET group, compared with 75.9%, 41.1%, and
36.5%, respectively, in the positive PET group (P 5 .0042;
Figure 2, A). The 1-, 3- and 5-year disease-free survivalsCause-specific survival
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Figure 2. Correlation between post-
treatment positron emission tomo-
graphic (PET) diagnosis at primary
tumor site and postoperative survival
by Kaplan–Meier analysis in neoadju-
vant group. A, Cause-specific survival
from data of all 50 patients. B,
Disease-free survival from data of 48
patients, excluding 2 cases of noncura-
tive resection (R2).y 2008
Higuchi et al General Thoracic Surgery
G
TSthat could be analyzed in 48 patients, excluding 2 with R2 re-
section, were 90.2%, 65.2%, and 65.2%, respectively, in the
negative PET group, compared with only 48.1%, 37.0%, and
37.0%, respectively, in the positive PET group (P 5 .0219;
Figure 2, B). These results indicate that posttreatment PET
diagnosis could distinguish patients with response who had
postoperative long-term survival from those without
response who had a poor prognosis.
Posttreatment PET Diagnosis and Patterns of Failure
The patterns of failure are shown in Table 2. There was no
significant difference in local recurrence rate between
positive PET (14.8%) and negative PET (9.5%) groups
(P 5 .5782). On the other hand, the proportion of patients
with distant metastasis in the positive PET group (48.1%)
was more than twice that in the negative PET group
(23.8%), although the difference did not reach statistical sig-
nificance (P 5 .08). Hematogenous spread was significantly
lower in the negative PET group (4.8%) than in the positive
PET group (37.0%, P 5 .0083). Furthermore, there were no
differences in tumor recurrence rate according to neoadjuvant
treatment modality (chemotherapy vs chemoradiotherapy)
between the positive and negative PET groups (Table 2).
Posttreatment PET Diagnosis and Prediction
of Long-term Outcome
We examined the usefulness of posttreatment PET diagnosis
for clinical prediction of long-term survival after surgery.
First, we determined the preoperative risk factors for long-
term survival with univariate Cox regression analysis (Table
3). The hazard ratio of posttreatment SUVmax greater than or
equal to 2.5 versus less than 2.5 was 3.628 (P 5 .0071), in-
dicating a strong correlation with postoperative survival. In
comparison, pretreatment clinical stage and clinical response
did not correlate with survival. Furthermore, pretreatment
TABLE 2. Posttreatment positron emission tomographic
diagnosis and patterns of failure
PET diagnosis
Pattern of failure Positive Negative P value
Local recurrence 4 (14.8%) 2 (9.5%) .5782
Distant metastasis 13 (48.1%) 5 (23.8%) .0800
M1(LYM) 5 3
Dissemination 0 1
Hematogenous 10 (37.0%) 1 (4.8%) .0083
Lung 3 0
Liver 3 1
Bone 4 0
Total recurrence 17/27 7/21
Chemotherapy 12/20 (60.0%) 4/13 (30.8%)
Chemoradiotherapy 5/7 (71.4%) 3/8 (37.5%)
Data represent numbers of patients. PET, Positron emission tomographic.The Journal of ThorSUVmax values (range of tested cutoff levels 4–15)
19,21 did
not correlate with survival, nor were reduction in SUVmax af-
ter treatment (range of tested cutoff levels 30%–80%)
11-13,16-18,20,21 and posttreatment SUVmax value less than 4,
23
which were previously reported to be associated with good
prognosis.11-13,16,18 Consequently, posttreatment PET diag-
nosis by SUVmax with a cutoff of 2.5 was the only significant
preoperative prognostic factor.
Discussion
The aims of multimodality cancer treatment are local control
of the tumor by reducing its size, systemic control by elimi-
nating micrometastases, and improvement in survival. Thus
the response to preoperative therapy should have an impact
on the prognosis after surgery. The response to cancer ther-
apy has been evaluated by morphologic assessment of the
relative change in tumor size before and after treatment.
Many clinical studies of neoadjuvant therapy, however,
have reported a lack of improvement of survival in patients
with clinically complete or partial response measured by
change in size, although such improvement has been noted
in patients with a complete or nearly complete histologic
response.3-6 These results suggest that treatment response
should be assessed by the absolute volume of posttreatment
residual tumor, rather than by relative change in tumor
TABLE 3. Univariate Cox regression analysis of
preoperative risk factors for long-term survival
Risk factor
Hazard
ratio
95% Confidence
interval
P
value
Sex, female vs male 1.293 0.482–3.467 .6097
Tumor location, lower or
gastroesophageal junction
vs upper or middle
1.264 0.540–2.956 .5895
Histologic differentiation (squamous
cell carcinoma), G1 or G2 vs G3
1.914 0.817–4.484 .1350
Clinical stage, IIA or IIB vs III or IV 1.199 0.536–2.678 .6588
M1(LYM), absence vs presence 1.199 0.536–2.678 .6588
Treatment, chemoradiotherapy
vs chemotherapy
0.711 0.304–1.663 .4312
Clinical response, complete or
partial response vs stable or
progressive disease
0.941 0.411–2.152 .8851
Pretreatment SUVmax, $8 vs ,8 1.324 0.388–4.518 .6535
Reduction rate of SUVmax, ,50%
vs $50%
1.967 0.625–6.189 .2475
Posttreatment SUVmax, ,4.0 vs $4.0 1.583 0.702–3.572 .2684
Posttreatment SUVmax, ,2.5 vs $2.5
(negative vs positive)
3.628 1.419–9.279 .0071
G1, Well-differentiated squamous cell carcinoma; G2, moderately differen-
tiated squamous cell carcinoma; G3, poorly differentiated squamous cell
carcinoma; SUVmax; maximum standardized uptake value for fluorodeoxy-
glucose on positron emission tomography.acic and Cardiovascular Surgery c Volume 136, Number 1 209
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been conducted to date by conventional modalities; however,
none seems satisfactory.7-10 How to predict preoperatively
information that is otherwise obtained by pathologic exami-
nation after surgery is the greatest challenge.
FDG-PET is a distinct newmetabolic diagnostic modality.
This study revealed that FDG-PET was directly predictive of
posttreatment residual tumor volume. FDG uptake correlated
with tumor size even after treatment (Figure E1), and a post-
treatment SUVmax less than 2.5, meaning no FDG accumula-
tion (negative), corresponded to grade 2 or better histologic
major response. Negative results of PET were correlated
with a residual tumor size smaller than 55 mm2 in all patients,
clearly distinguishing histologic response from nonresponse
(Table 1).Moreover, the negative PET group showed a signif-
icantly better survival than did the positive PET group in the
analysis of median survival, cause-specific survival (P 5
.0042), and disease-free survival (P 5 .0219; Figure 2).
Thus posttreatment FDG-PET diagnosis appears to be preop-
eratively predictive of both histologic major response and
postoperative survival.
Table 4 summarizes the results of 15 clinical studies of
response evaluation to neoadjuvant therapy by FDG-PET in
patients with esophageal carcinoma. The studies are divided
into two groups according to the criteria of response to such
therapy. The first group consists of 12 studies that assessed
the response by measuring FDG uptake before and after treat-210 The Journal of Thoracic and Cardiovascular Surgery c Julyment (reduction rate group),11-22 whereas the second group
comprises 3 studies, including our own, that examined the
response by measuring posttreatment SUVmax (posttreatment
group).23,24 We reviewed the results of assessment of FDG-
PET as a tool for evaluating the histologic response to neoad-
juvant therapy (complete or nearly complete response) and
postoperative survival. The former was examined in 11 stud-
ies (10 studies in rate of reduction of FDG uptake, references
11-15, and 17-21; 1 study in posttreatment, our study), and
the latter was investigated in 8 studies (5 studies in reduction
rate, references 11-13, 16, and 18; 3 studies in posttreatment,
references 23, and 24). The results showed that 8 of 11 histo-
logic response studies 7 studies in reduction rate, references
11-14, 17, 18, and 20; 1 study in posttreatment, our study)
and 7 of 8 survival-outcome studies (4 studies in reduction
rate, references 11-13, and 18; 3 studies in posttreatment, ref-
erences 23, and 24) agreed on the suitability of FDG-PET for
predicting the histologic response and survival after neoadju-
vant therapy, despite the use of different response criteria in
these studies. Except for 2 studies, however, all other stud-
ies11-14,17,18,20,23,24 included small population samples of 17
to 37 patients who underwent surgery. Thus relatively
large-scale analyses were limited to 2 studies only: the report
of Swisher and colleagues23 for 71 patients with mainly ade-
nocarcinoma and our own report of 50 patients with SCC.
Both studies emphasized the usefulness of posttreatment
SUVmax as an indicator for response evaluation. The cutoffTABLE 4. Summary of reported studies that evaluated response to neoadjuvant therapy by positron emission tomography
with fludeoxyglucose F 18 in patients with esophageal carcinoma
Study No. AC/SCC Therapy Timing of PET R criteria
Reduction rate group
Brcher et al,11 2001 27 0/27 CRT 3 wk postcompletion Reduction rate of SUVmean .52%
Weber et al,12 2001 40 40/0 ChT 2 wk postinitiation Reduction rate of SUVmean .35%
Flamen et al,13 2002 36 9/27 CRT 4 wk postcompletion Reduction rate of SUVmax .80%
Kato et al,14 2002 10 0/10 CRT 2 wk postcompletion FDG uptake length decrease .50%
Arslan et al,15 2002 24 22/2 CRT 4 wk postcompletion Reduction of FDG uptake positive or negative
Downey et al,16 2003 39 26/13 CRT U Reduction rate of SUVmax .60%
Kroep et al,17 2003 13 11/1 ChT 1 or 2 wk postcompletion Reduction rate of SUVmean .40%
Wieder et al,18 2004 38 0/38 CRT 4 wk postinitiation Reduction rate of SUVmean .30%
Song et al,19 2005 32 0/32 CRT 4 wk postcompletion Reduction of SUVmean, initial SUV .4.0
Westerterp et al,20 2006 26 20/6 CRT
plus HT
2 wk postinitiation Reduction rate of SUVmean .31%, initial
SUVmax .15, SUVmax decrease .10
Levine et al,21 2006 64 52/9 CRT Postcompletion
Gillham et al,22 2006 32 27/5 CRT 1 wk postinitiation
Posttreatment group
Swisher et al,23 2004 83 73/10 CRT Postcompletion and preoperative Reduction of SUVmean, NE about value,
posttherapy SUVmax ,4.0
Duong et al,24 2006 53 24/27 CRT 4 or 5 wk postcompletion Posttherapy FDG uptake negative
Current study 50 0/50 CRT/ChT 2 (ChT) or 4 (CRT) wk postcompletion Posttherapy SUVmax ,2.5
R, Response; non-R, nonresponse; AC, adenocarcinoma; SCC, squamous cell carcinoma; PET, positron emission tomography;MST, median survival time; CRT,
chemoradiotherapy; SUV, standardized uptake value of fluorodeoxyglucose; NE, not evaluated; ChT, chemotherapy; FDG, fluorodeoxyglucose; HT, hyper-
thermia; U, unknown, not described; NS, not significant.2008
Higuchi et al General Thoracic Surgeryvalues for major response were 4.0 in the study of Swisher
and colleagues23 and 2.5 in our own study. This difference
may result from the difference in cell type. Univariate Cox re-
gression analysis demonstrated that posttreatment SUVmax
(cutoff value 2.5) was the only preoperative prognostic factor
for esophageal SCC in our study, although other response cri-
teria reported previously, such as reduction rate of SUVmax,
were included in our analysis (Table 3). Consequently, post-
treatment SUVmax is the most promising noninvasive param-
eter for accurate, objective, and preoperative prediction of
histopathologic response to preoperative treatment and prog-
nosis. Moreover, to our knowledge, ours is the first report of
a large-scale analysis of the response evaluation by FDG-PET
for patients with esophageal SCC.
Failure pattern analyses revealed that the negative PET
group showed a lower rate of distant metastases, especially
an extremely lower rate of hematogenous metastases (4.8%),
than did the positive PET group (37.0%, P 5 .0083; Table
2). Therefore responses such as disappearance of FDG uptake
after treatment might suggest downstaging from systemic dis-
ease to local disease as a result of control of potential sys-
temic micrometastases by first-line therapy. In this context,
patients with negative posttreatment PET results could be
good candidates for subsequent surgery. On the other
hand, patients with positive posttreatment PET results
showed high tumor recurrence (63.0%); in other words,
both the local and systemic controls were insufficient.The Journal of ThoFrom this point of view, additional preoperative chemother-
apy or chemoradiotherapy might lead to improvement in out-
come, although the optimal treatment for patients without
response is still unclear. Nevertheless, FDG-PET is helpful
for predicting histologic response versus nonresponse before
surgery, allowing selection of the ensuing clinical manage-
ment according to the expected response.
Also, FDG-PET has another advantage of possibly check-
ing the presence or absence of distant metastases by whole-
body scanning. Surgical indication in multimodality treatment
has three conditions. First is that micrometastases outside the
surgically resectable field be eliminated, second is that there
are no distant metastases in the whole body, and last is that
long-term survival after surgery be anticipated. FDG-PET
can provide important and definitive information for all
conditions preoperatively, accurately, and noninvasively.
Even FDG-PET, however, could not predict pathologi-
cally complete response. As shown in Table 1, residual
tumors measuring less than 55 mm2 cannot be visualized by
FDG-PET, and thus it is impossible to distinguish pathologi-
cally complete response fromminimal residual tumor smaller
than 55 mm2. If pathologically complete response could be
predicted accurately, there would be no need for surgery in
such cases. Previous studies, however, reported that false-neg-
ative results in patients withminimal residual tumors despite of
lack of FDG uptake constituted 29% to 82% of negative PET
results.11-15,17-19,21 Molecular biologic approaches mayG
TSHistologic response Survival, R vs non-R
Surgical patients (No.) Sensitivity Specificity MST (mo) 2-y P value
24 100% 55% 22.5 vs 6.7 NE ,.0001
37 89% 75% NE 60% vs 37% .04
30 71% 82% 16.3 vs 8 NE .002
10 100% 50% NE NE NE
20 61% 33% NE NE NE
17 NE NE NE 89% vs 63% .088
12 100% 86% NE NE NE
33 93% 88% 38 vs 18 79% vs 38% .011
32 27% 95% NE NE NE
24 75% 75% NE NE NE
48 42% 89% NE NE NE
32 U U NE NE NS
71 U 95% NE 60% vs 33% .01
17 NE NE NE 100% vs ,60% ,.001
50 90% 90% .84.2 vs 18.2 90% vs 41% .0042
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G
TSprovide useful information but need to be investigated thor-
oughly in future studies. Esophagectomy should therefore still
be considered the therapeutic choice, as long asmicroscopic re-
sidual tumor cannot be ruled out completely.
We treated malignant tumors of heterogeneous biological
activity and patients with heterogeneous immunologic re-
sponse. Nevertheless, treatment was applied with a uniform
protocol, as though all patientswere from a homogeneous pop-
ulation. Survival benefits of such regimens are observed only
in those with response, whereas the prognosis of those without
a response seems to be even worse than that of patients treated
by surgery alone. It is therefore indispensable for improvement
of treatment outcome and quality of life to predict the response
to first-line therapy and tailor the second-line therapy accord-
ing to the response. In this context, posttreatment FDG-PET
can have an impact on any decision either for or against
additional preoperative treatment in individual cases. Further
large-scale multicenter studies are needed to investigate the
feasibility of FDG-PET as the optimal standard for evaluation
of response to chemotherapy and chemoradiotherapy.
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Figure E1. Relationship between histologic response grade in pri-
mary tumor after chemoradiotherapy and residual tumor size. Size
of 33 mm2, indicated by arrow, represents cutoff value used to dis-
tinguish between grade 1 or worse histologic nonresponse and
grade 2 or better histologic response.G
TS
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G
TSFigure E2. Example of positron emission tomo-
graphic imaging before (A) after (B) chemother-
apy, with histologic finding of residual tumor
(C). Maximum standardized uptake value of pri-
mary tumor decreased from 15.59 to 1.63 after ther-
apy. Size of residual tumor was 1.3 mm2, and
histologic response was assessed as grade 2.212.e2 The Journal of Thoracic and Cardiovascular Surgery c July 2008
Higuchi et al General Thoracic SurgeryTABLE E1. Patient characteristics
Patients (No.) 50
Sex ratio (male/female) 41:9
Age (y, median and range) 62.2 (44–77)
Location (No.)
Cervical 11
Upper thoracic 5
Middle thoracic 17
Lower thoracic 17
Pretreatment clinical stage (No.)
I 0
IIA 0
IIB 0
III 24
IVA 11
IVB 15
Preoperative treatment (No.)
Chemoradiotherapy 15
Chemotherapy 35
Surgery (No.)
Cervical esophagectomy 11
Subtotal esophagectomy 39
Resectability (No.)
R0 48
R1 0
R2 2
R0, No residual tumor cell; R1, microscopic residual tumor cells; R2, macro-
scopic residual tumor cells.G
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